# Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm

> **NCT04939909** · EARLY_PHASE1 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 50 (estimated)

## Conditions studied

- Blepharospasm

## Interventions

- **DRUG:** Botulinum toxin type A

## Key facts

- **NCT ID:** NCT04939909
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-12
- **Primary completion:** 2021-12-24
- **Final completion:** 2022-07-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04939909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04939909, "Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04939909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*